In addition, the trial was conducted according to regulatory standards and comprised four renal impairment groups (including a group with ESRD) with more than ten subjects in each group and included a reference group with normal renal function that was comparable with respect to baseline characteristics [18, 19]
Results Data from one phase 2 trial, five international phase 3 trials and one regional phase 3 trial in Japan, each with at least one MACE-4 event, were included in this meta-analysis (Supplementary Table 1)
This distinguishes it from dual agonists such as tirzepatide and single agonists such as semaglutide, though no head-to-head comparative trials have been conducted and no superiority claims can be made at this stage
Are Zepbound, Semaglutide, and Wegovy FDA-approved for weight loss
BPC-157 Supplies Needed Affiliate disclosure: PDP may earn a commission when you use eligible supplier links, at no extra cost to you